^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
IBI-389
i
Other names: IBI-389, IBI389, IBI 389
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Innovent Biologics
Drug class:
CD3 agonist, CLDN18.2 inhibitor
Related drugs:
12ms
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (clinicaltrials.gov)
P1, N=320, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Phase classification: P1a/1b --> P1 | Trial completion date: Apr 2024 --> Sep 2024 | Trial primary completion date: Dec 2023 --> Apr 2024
Phase classification • Trial completion date • Trial primary completion date • Combination therapy • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
1year
Safety, tolerability and preliminary efficacy of IBI389 in subjects with advanced pancreatic cancer: An open-label phase II study (ChiCTR2300077565 )
P2, N=42, Not yet recruiting, First Affiliated Hospital of Anhui Medical University
New P2 trial • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 positive
|
gemcitabine • albumin-bound paclitaxel • IBI-389
2years
Safety and Efficacy of IBI389 Single Agent, and in Combination With Sintilimab, in Patients With Advanced Malignancies (clinicaltrials.gov)
P1a/1b, N=320, Recruiting, Innovent Biologics (Suzhou) Co. Ltd. | Not yet recruiting --> Recruiting
Enrollment open • Combination therapy • Metastases
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
3years
Safety and Efficacy of IBI389 Single Agent and in Combination With Sintilimab in Patients With Advanced Malignancies (clinicaltrials.gov)
P1a/1b, N=320, Not yet recruiting, Innovent Biologics (Suzhou) Co. Ltd.
Clinical • New P1 trial • Combination therapy
|
CLDN18 (Claudin 18)
|
CLDN18.2 expression
|
Tyvyt (sintilimab) • IBI-389
Share via
